|
2020
|
Invention
|
Anti-tnfr2 antibodies and uses thereof. Disclosed herein are anti-TNFR2 antibodies, therapeutic c... |
|
2019
|
Invention
|
Anti-tnfr2 antibodies and uses thereof.
Anti-TNFR2 antibodies which bind to particular human TNF... |
|
|
Invention
|
Anti-tnfr2 antibodies and uses thereof. Anti-TNFR2 antibodies which bind to particular human TNFR... |
|
2018
|
Invention
|
Compositions and methods for delivering nucleic acid to a cell.
Provided are novel compositions ... |
|
|
Invention
|
4-1bb agonist and cd40 agonist bispecific molecules. Disclosed are bispecific molecules that comp... |
|
|
Invention
|
Bispecific 4-1bb agonist molecules. Disclosed are bispecific molecules that comprise a 4-1BB agon... |
|
|
Invention
|
Epha2-targeted docetaxel -generating liposomes in combination with an agent that impedes regulato... |
|
|
Invention
|
Tnf superfamily fusion polypeptides. Engineered 4-1BBL polypeptides and Fc-4-1BBL fusion polypept... |
|
|
Invention
|
Anti-fgfr antibodies and methods of use.
Anti-FGFR antibodies which bind to particular isoforms ... |
|
|
Invention
|
Anti-fgfr antibodies and methods of use. Anti-FGFR antibodies which bind to particular isoforms o... |
|
2017
|
Invention
|
Combination of an erbb3 inhibitor, topoisomerase i inhibitor, and an alkylating agent to treat ca... |
|
|
Invention
|
Heteromeric polypeptides. Proteins comprising CH3 variants for generation of heteromeric polypept... |
|
|
Invention
|
Combination therapies comprising anti-erbb3 agents.
Disclosed are methods and compositions for i... |
|
|
Invention
|
Antibodies against epidermal growth factor receptor (egfr) and uses thereof.
Anti-EGFR antibodie... |
|
|
Invention
|
Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic... |
|
|
Invention
|
Methods for selecting and treating patients with a trail-based therapeutic or death receptor agon... |
|
|
Invention
|
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemoth... |
|
|
Invention
|
Combination therapies for treating her2-positive cancers that are resistant to her2-targeted ther... |
|
|
Invention
|
Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies.
... |
|
|
Invention
|
Dosage and administration of anti-egfr therapeutics.
Methods for optimizing a therapeutic respon... |
|
|
Invention
|
Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and meth... |
|
|
Invention
|
Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antib... |
|
|
Invention
|
Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing pre... |
|
|
Invention
|
Nanoliposomal targeting of ephrin receptor a2 (epha2) and related diagnostics.
EphA2 targeted do... |
|
|
Invention
|
Engineered trail for cancer therapy.
Engineered single chain trail molecules are provided, as ar... |
|
|
Invention
|
Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-lipos... |
|
|
Invention
|
Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions.
EphA2-targe... |
|
|
Invention
|
Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions. EphA2-target... |
|
|
Invention
|
Engineered trail for cancer therapy. Engineered single chain trail molecules are provided, as are... |
|
|
Invention
|
Nanoliposomal targeting of ephrin receptor a2 (epha2) and related diagnostics. EphA2 targeted dox... |
|
|
Invention
|
Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an ant... |
|
|
Invention
|
Dosage and administration of combination therapies comprising targeted antibodies uses and method... |
|
|
Invention
|
Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof.
Provided by th... |
|
|
Invention
|
Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof. Provided by the... |
|
|
Invention
|
Treatment of her2-intermediate cancer. Patients with gastric cancer or breast cancer, for example... |
|
|
Invention
|
Dosage and administration of combination therapies comprising istiratumab, uses and methods of tr... |
|
|
Invention
|
Cartilage-binding fusion proteins.
Provided herein are fusion proteins comprising a first domain... |
|
2016
|
Invention
|
Dosage and administration of anti-egfr therapeutics. Methods for optimizing a therapeutic respons... |
|
|
Invention
|
Methods, systems and products for predicting response of tumor cells to a therapeutic agent and t... |
|
|
Invention
|
Tandem fc bispecific antibodies.
Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs... |
|
|
Invention
|
Bispecific binding agents targeting the igf-1r and erbb3 pathways and uses thereof.
Disclosed ar... |
|
|
Invention
|
Disulfide-stabilized fabs.
Provided are antibody fragments (Fabs) wherein native disulfide bonds... |
|
|
Invention
|
Methods and compositions for improving outcomes of liposomal chemotherapy.
Materials and methods... |
|
|
Invention
|
Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers.
Provi... |
|
|
Invention
|
Combination cancer therapies.
The disclosure provides methods of treatment for cancer in patient... |
|
|
P/S
|
Pharmaceutical preparations for the diagnosis and treatment
of cancer, oncological disorders, au... |
|
2015
|
Invention
|
Predicting tumor responses to antibodies against hepatocyte growth factor (hgf) and/or its cognat... |
|
2003
|
P/S
|
Scientific, biotechnology, and pharmaceutical product research and development services, namely, ... |
